AMLX Stock Catalyst: Amylyx Pharmaceuticals Announces Topline Results from Phase 3 LUCIDITY Trial of Avexitide

Aug 17, 2026 · 4:00pm ET

Company to reveal outcomes for Avexitide in post-bariatric hypoglycemia patients.

Max move

+65.1%

High of day $35.39

Sparker timei

4:00pm ET

AMLX · Aug 17, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced on August 18, 2026, that it will disclose the topline results from its Phase 3 LUCIDITY clinical trial evaluating Avexitide for the treatment of post-bariatric hypoglycemia.

The trial aimed to assess the efficacy and safety of Avexitide in this patient population. Further details on the results will be provided by the company.

As of the latest data, Amylyx Pharmaceuticals has a free float of 82,381,278 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time AMLX sparks.

Download Sniper App →

Catch the next AMLX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →